Cortisol Modulation
Stories
Careers
Contact
Home
About
Our Team
Products
Medical Information Request
Science
Pipeline and Clinical Trials
Cortisol Modulation
Therapeutic Areas
Publications
Investigator Initiated Studies
Resources
Grants
Compassionate use
State Required Notice
Investors
Overview
Press Releases
Events
Corporate Governance
Analyst Coverage
Stock Information
SEC Filings
Search
Menu
Menu
Home
About
Teams
Products
Medical Information Request
Science
Pipeline and Clinical Trials
Cortisol Modulation
Therapeutic Areas
Publications
Investigator Initiated Studies
Resources
Grants
Compassionate use
State Required Notice
Stories
Careers
Contact
Investors
Overview
Press Releases
Events
Corporate Governance
Analyst Coverage
Stock Information
SEC Filings
Privacy Notice
Terms of Use
Site Map
Stories
and perspectives.
Honoring Ildaura Murillo-Rohde
Article:
Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes
Article:
Navigating Hypercortisolism: Deile’s Story
Article:
Corcept Announces Presentation of Results From Prevalence Phase of CATALYST Clinical Trial at American Diabetes Association’s Scientific Sessions
Press Release: Jun 24, 2024
Celebrating Dr. Neena Schwartz
Article:
Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism (Cushing’s Syndrome)
Press Release: May 28, 2024
What is Hypercortisolism?
Featured Content:
Final Overall Survival Data From a Randomized, Open-Label, Phase 2 Study of Relacorilant, a Selective Glucocorticoid Receptor Modulator, in Combination With Nab-Paclitaxel in Patients With Recurrent Platinum-Resistant Ovarian Cancer
Publication: March 18, 2024
Cushing’s Syndrome: A Patient Advocate Perspective
Article:
We are Corcept.
Video:
Founding Corcept
Article:
JOIN OUR COMMUNITY
Scroll to top